Dyne Therapeutics, Inc. $DYN is Atlas Venture Life Science Advisors LLC's 2nd Largest Position

Key Points

• Atlas Venture Life Science Advisors reduced its Dyne Therapeutics stake by 25.5% in the second quarter, but still held 6.8 million shares worth about $151 million, making DYN its second-largest position.
• Dyne shares opened at $24.95, near their 52-week high, while the company reported a quarterly loss of $1.08 per share—worse than analysts’ expected loss of $0.75. Analysts nevertheless maintain a “Moderate Buy” consensus with an average price target of $34.42.
• Insiders sold approximately 4.14 million shares worth $99.4 million over the past 90 days, including a director’s sale of 2.16 million shares under a pre-arranged trading plan.

Atlas Venture Life Science Advisors LLC trimmed its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 25.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,800,099 shares of the company's stock after selling 2,330,366 shares during the quarter. Dyne Therapeutics accounts for 17.1% of Atlas Venture Life Science Advisors LLC's holdings, making the stock its 2nd largest holding. Atlas Venture Life Science Advisors LLC owned about 3.64% of Dyne Therapeutics worth $151,030,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. grew its position in shares of Dyne Therapeutics by 523.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company's stock worth $343,085,000 after buying an additional 14,727,667 shares in the last quarter. BlackRock Inc. acquired a new stake in Dyne Therapeutics in the second quarter valued at approximately $275,500,000. Jupiter Topco LLC purchased a new position in Dyne Therapeutics in the second quarter worth approximately $266,634,000. Vanguard Group Inc. lifted its stake in Dyne Therapeutics by 14.9% in the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company's stock worth $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. Finally, State Street Corp grew its holdings in Dyne Therapeutics by 27.0% during the 4th quarter. State Street Corp now owns 6,692,745 shares of the company's stock worth $130,910,000 after acquiring an additional 1,423,828 shares in the last quarter. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Stock Down 0.8%

Shares of NASDAQ:DYN opened at $24.95 on Friday. The firm has a 50 day simple moving average of $24.74 and a 200-day simple moving average of $20.33. Dyne Therapeutics, Inc. has a twelve month low of $11.92 and a twelve month high of $27.31. The company has a current ratio of 12.02, a quick ratio of 12.02 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $4.66 billion, a PE ratio of -7.49 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.33). On average, equities analysts predict that Dyne Therapeutics, Inc. will post -3.47 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In other news, CFO Erick Lucera sold 2,362 shares of Dyne Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the transaction, the chief financial officer directly owned 121,563 shares of the company's stock, valued at $2,476,238.31. The trade was a 1.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Jason P. Rhodes sold 2,160,516 shares of the company's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director owned 428,946 shares of the company's stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 4,139,196 shares of company stock worth $99,449,852. 9.46% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on DYN. HC Wainwright reissued a "buy" rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research report on Monday, August 17th. Morgan Stanley decreased their price objective on shares of Dyne Therapeutics from $47.00 to $45.00 and set an "overweight" rating for the company in a research report on Friday, July 31st. TD Cowen initiated coverage on shares of Dyne Therapeutics in a research note on Friday, June 26th. They set a "buy" rating for the company. Wall Street Zen lowered Dyne Therapeutics from a "sell" rating to a "strong sell" rating in a report on Saturday, August 1st. Finally, Cantor Fitzgerald initiated coverage on Dyne Therapeutics in a report on Thursday, July 23rd. They issued an "overweight" rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Dyne Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $34.42.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company's proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne's lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.

Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source